open access

Vol 76, No 8 (2018)
Original articles
Published online: 2018-05-08
Submitted: 2017-10-26
Accepted: 2018-05-08
Get Citation

A serial three- and nine-year optical coherence tomography evaluation of neoatherosclerosis progression after sirolimus- and paclitaxel- -eluting stent implantation

Mariusz Tomaniak, Janusz Kochman, Łukasz Kołtowski, Arkadiusz Pietrasik, Adam Rdzanek, Jacek Jąkała, Klaudia Proniewska, Krzysztof Malinowski, Dorota Ochijewicz, Krzysztof J. Filipiak, Salvatore Brugaletta, Grzegorz Opolski
DOI: 10.5603/KP.a2018.0109
·
Kardiol Pol 2018;76(8):1251-1256.

open access

Vol 76, No 8 (2018)
Original articles
Published online: 2018-05-08
Submitted: 2017-10-26
Accepted: 2018-05-08

Abstract

Background: Early-generation drug-eluting stents (DESs) have been shown to accelerate neoatherogenesis. Limited optical coherence tomography (OCT) data on the very long-term neoatherosclerotic progression after DES implantation are available.

Aim: The aim of this study was a serial OCT evaluation of neoatherosclerosis at three and nine years after implantation of sirolimus-eluting stents (SESs) and paclitaxel-eluting stents (PESs).

Methods: Consecutive patients undergoing elective percutaneous coronary intervention with SES (Cypher, Cordis) or PES (Taxus, Boston Scientific) were included in this single-centre, longitudinal study. OCT analysis was performed after three and nine years by an independent core laboratory.

Results: A total of 39 OCT recordings were assessed at three years after the index procedure; of them, 22 (eight SES and 14 PES) OCT pullbacks were evaluated in a paired analysis at three and nine years post implantation. Overall, neoatheroscle­rosis was identified in 23.1% of stents at three years and in 30.8% at nine years after the index procedure (p = 0.289). No features of significant neoatherosclerotic progression were found in either group between three- and nine-year assessment.

Conclusions: At nine years after implantation of early-generation DES no significant neoatherosclerotic progression was observed among patients with uneventful follow-up at three years after PCI, as assessed by OCT. These observations need to be confirmed in larger studies including the current generation of DESs.

Abstract

Background: Early-generation drug-eluting stents (DESs) have been shown to accelerate neoatherogenesis. Limited optical coherence tomography (OCT) data on the very long-term neoatherosclerotic progression after DES implantation are available.

Aim: The aim of this study was a serial OCT evaluation of neoatherosclerosis at three and nine years after implantation of sirolimus-eluting stents (SESs) and paclitaxel-eluting stents (PESs).

Methods: Consecutive patients undergoing elective percutaneous coronary intervention with SES (Cypher, Cordis) or PES (Taxus, Boston Scientific) were included in this single-centre, longitudinal study. OCT analysis was performed after three and nine years by an independent core laboratory.

Results: A total of 39 OCT recordings were assessed at three years after the index procedure; of them, 22 (eight SES and 14 PES) OCT pullbacks were evaluated in a paired analysis at three and nine years post implantation. Overall, neoatheroscle­rosis was identified in 23.1% of stents at three years and in 30.8% at nine years after the index procedure (p = 0.289). No features of significant neoatherosclerotic progression were found in either group between three- and nine-year assessment.

Conclusions: At nine years after implantation of early-generation DES no significant neoatherosclerotic progression was observed among patients with uneventful follow-up at three years after PCI, as assessed by OCT. These observations need to be confirmed in larger studies including the current generation of DESs.

Get Citation

Keywords

optical coherence tomography, early-generation drug-eluting stent, neoatherosclerosis

About this article
Title

A serial three- and nine-year optical coherence tomography evaluation of neoatherosclerosis progression after sirolimus- and paclitaxel- -eluting stent implantation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 8 (2018)

Pages

1251-1256

Published online

2018-05-08

DOI

10.5603/KP.a2018.0109

Bibliographic record

Kardiol Pol 2018;76(8):1251-1256.

Keywords

optical coherence tomography
early-generation drug-eluting stent
neoatherosclerosis

Authors

Mariusz Tomaniak
Janusz Kochman
Łukasz Kołtowski
Arkadiusz Pietrasik
Adam Rdzanek
Jacek Jąkała
Klaudia Proniewska
Krzysztof Malinowski
Dorota Ochijewicz
Krzysztof J. Filipiak
Salvatore Brugaletta
Grzegorz Opolski

References (23)
  1. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008; 118(11): 1138–1145.
  2. Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012; 59(23): 2051–2057.
  3. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation. 2011; 123(25): 2954–2963.
  4. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370(9591): 937–948.
  5. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369(9562): 667–678.
  6. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011; 57(11): 1314–1322.
  7. Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012; 59(12): 1058–1072.
  8. Stettler R, Dijkstra J, Räber L, et al. Neointima and neoatherosclerotic characteristics in bare metal and first- and second-generation drug-eluting stents in patients admitted with cardiovascular events attributed to stent failure: an optical coherence tomography study. EuroIntervention. 2018; 13(15): e1831–e1840.
  9. Räber L, Baumgartner S, Garcia H, et al. Long-Term vascular healing in response to sirolimus- and paclitaxel-eluting stents. JACC: Cardiovasc Interv. 2012; 5(9): 946–957.
  10. Gomez-Lara J, Brugaletta S, Jacobi F, et al. Five-year optical coherence tomography in patients with st-segment-elevation myocardial infarction treated with bare-metal versus everolimus-eluting stents. Circ Cardiovasc Interv. 2016; 9(10): e003670.
  11. Song L, Mintz GS, Yin D, et al. Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents. Int J Cardiovasc Imaging. 2017; 33(8): 1115–1124.
  12. Nakamura D, Attizzani GF, Toma C, et al. Failure mechanisms and neoatherosclerosis patterns in very late drug-eluting and bare-metal stent thrombosis. Circ Cardiovasc Interv. 2016; 9(9): e003785.
  13. Prati F, Guagliumi G, Mintz GS, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J. 2012; 33(20): 2513–2520.
  14. Taniwaki M, Windecker S, Zaugg S, et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J. 2015; 36(32): 2167–2176.
  15. Takano M, Yamamoto M, Mizuno M, et al. Late vascular responses from 2 to 4 years after implantation of sirolimus-eluting stents: serial observations by intracoronary optical coherence tomography. Circ Cardiovasc Interv. 2010; 3(5): 476–483.
  16. Nakamura D, Lee Y, Yoshimura T, et al. Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study. EuroIntervention. 2014; 10(8): 924–933.
  17. Nakazawa G, Finn AV, Vorpahl M, et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011; 57(4): 390–398.
  18. Gao L, Park SJ, Jang Y, et al. Comparison of Neoatherosclerosis and Neovascularization Between Patients With and Without Diabetes: An Optical Coherence Tomography Study. JACC Cardiovasc Interv. 2015; 8(8): 1044–1052.
  19. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015; 36(32): 2147–2159.
  20. Yonetsu T, Kato K, Kim SJ, et al. Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry. Circ Cardiovasc Imaging. 2012; 5(5): 660–666.
  21. Ali ZA, Roleder T, Narula J, et al. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013; 6(5): 507–517.
  22. Yonetsu T, Kim JS, Kato K, et al. Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography. Am J Cardiol. 2012; 110(7): 933–939.
  23. Ishida K, Ortega-Paz L, Brugaletta S, et al. Very Late Stent Thrombosis Induced by Neoatherosclerosis 6 Years after Paclitaxel Eluting Stent Implantation: Optical Coherence Tomography Imaging. JSM Atheroscler. 2016; 1(2): 1007.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl